Posters et résumés présentés au AACR 2021
April 11, 2021 - … drugs through SORT1+ Technology™: A new targeted approach for treatment of ovarian and endometrial cancers: Cliquez … drugs through SORT1+ Technology™: A new targeted approach for treatment of ovarian and endometrial cancers: Cliquez … drugs through SORT1+ Technology™: A new targeted approach for treatment of ovarian and endometrial cancers: Cliquez …
Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended
November 23, 2021 - … Commission (the " SEC ") on Form F-10. The filing is made for the purpose of restoring the original financing capacity … securities covered by the shelf prospectus are offered for sale, a prospectus supplement containing specific information … statement is available on our SEDAR profile at www.sedar.com or on EDGAR at www.sec.gov . Alternatively, a copy of …
Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1
October 26, 2021 - … Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1 … on Trogarzo ® , please contact medinfo.eu@theratech.com . About Theratechnologies Theratechnologies (TSX: TH) … Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant …
Theratechnologies Announces Publication in Frontiers in Oncology Journal Highlighting SORT1+ Technology™ for Targeting SORT1-Mediated Vasculogenic Mimicry
October 22, 2021 - … in Oncology Journal Highlighting SORT1+ Technology™ for Targeting SORT1-Mediated Vasculogenic Mimicry … in Oncology Journal Highlighting SORT1+ Technology™ for Targeting SORT1-Mediated Vasculogenic Mimicry Oct 22, … is available on the Company's website at www.theratech.com , on SEDAR at www.sedar.com and on EDGAR at www.sec.gov . …
Theratechnologies annonce une publication dans la revue Frontiers in Oncology soulignant la plateforme SORT1+ Technology™ pour cibler le mimétisme vasculogénique médié par la SORT1
October 22, 2021 - … in Oncology et s’intitule « New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry … sur le site Web de la Société à l’adresse www.theratech.com , sur SEDAR à www.sedar.com et sur EDGAR à www.sec.gov . Énoncés prospectifs Le …
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2021 and Provides Business Update
October 13, 2021 - … Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2021 and Provides Business … is available on the Company's website at www.theratech.com , on SEDAR at www.sedar.com and on EDGAR at www.sec.gov … body negatively affecting the marketing, promotion or sale of EGRIFTA SV ® and Trogarzo ® in countries where such …
Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study
September 22, 2021 - … Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study Theratechnologies … is available on the Company's website at www.theratech.com , on SEDAR at www.sedar.com and on EDGAR at www.sec.gov … body negatively affecting the marketing, promotion or sale of Trogarzo ® in countries where such products are …
July 21, 2021 - … TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast … J-C, et al. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast …
Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science
August 13, 2021 - … of data from its preclinical research of TH1902 for the treatment of sortilin-positive triple negative breast … is titled “ TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast … is available on the Company's website at www.theratech.com , on SEDAR at www.sedar.com and on EDGAR at www.sec.gov …
Theratechnologies annonce la publication de données précliniques sur le TH1902 dans Cancer Science
August 13, 2021 - … est intitulé « TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast … disponibles sur le site Web de la Société au www.theratech.com , sur SEDAR au www.sedar.com et sur EDGAR au www.sec.gov . Information prospective Le …